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Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors,
and effect of neuromuscular monitoring and reversal agents
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Background/aim: The aim of this study was to determine the incidence of residual neuromuscular block (RNMB) in a tertiary care
hospital. Secondary goals were to examine the characteristics of the use of intraoperative neuromuscular monitoring (NMM) and
different reversal agents by the attending anesthesiologists, and to determine the factors related to the patient and perioperative processes
on the development of RNMB.
Materials and methods: The patients’ arrival time at the postanesthesia care unit was accepted as point zero (T0). The acceleromyography
of the patients’ adductor pollicis muscle was monitored for NMM. Train of four ratios (TOFRs) were recorded at 0, 10, 20, and 30 min.
A TOFR < 0.9 was defined as RNMB. Patients’ demographic and perioperative data were also recorded.
Results: A total of 216 patients completed the study. RNMB was observed in 47 patients (21.8%). Seventy-eight patients (36%) were
followed up with NMM. Neostigmine and sugammadex were used in 174 (80.5%) and 42 (19.5%) patients, respectively, and they were
both underdosed (21.2 ± 3.0 mcg/kg and 1.5 ± 0.7 mg/kg, respectively). Use of neostigmine and absence of NMM were risk factors for
RNMB (p: 0.01 and 0.001, respectively) along with the number of additional doses (>1 doses, p ≤ 0.02) and the timing of the last dose of
rocuronium (<88 min, p ≤ 0.01). None of the patients who received both NMM and sugammadex experienced RNMB.
Conclusion: The RNMB incidence was found to be 21.8%. The main reasons of it were the lack of intraoperative NMM and inappropriate
use of reversal agents. Despite strong recommendations, the use of NMM is still insufficient and reversal agents are still underdosed.
Key words: Residual neuromuscular block, neuromuscular monitoring, neostigmine, sugammadex

1. Introduction
Neuromuscular blocker drugs (NMBDs) are frequently
used during anesthesia to facilitate tracheal intubation,
maintain mechanical ventilation, and facilitate surgeries.
Owing to an insufficient reversal of these agents, residual
neuromuscular block (RNMB) may be observed during
the postoperative period. RNMB is defined as a train-offour ratio (TOFR) < 0.9 [1].
RNMB has been reported in 13% to 88% of patients in
the postanesthesia care unit (PACU) [1-6]. RNMB in the
early postoperative period is related to delayed tracheal
extubation, acute respiratory events (hypoxemia and
airway obstruction), muscle weakness, prolonged PACU
stay, and increased risk of postoperative pulmonary
complications [7, 8]. Therefore, the most recent guideline
on the use of NMBDs and reversal agents, published
in 2020, recommends qualitative or quantitative
neuromuscular evaluation before administration of a

reversal agent. It is recommended that, if the monitored
TOF count is 4, then neostigmine (40 mcg/kg) + atropine
(0.02 mg/kg) can be administered. When sugammadex
is used, the minimum dose suggested is 2 mg/kg in
accordance with the neuromuscular monitoring (NMM)
data [9].
Studies published before the 2020 guideline showed
that very few clinicians acknowledged the necessity of
NMM and routinely performed it in their cases [10].
Moreover, reversal agents are frequently underdosed in
light of recent recommendations [8,11]. To the best of our
knowledge, no observational studies have examined the
use of NMM and reversal agents after the aforementioned
guideline was published.
The primary objective of this study was to determine
the incidence of RNMB in a tertiary care hospital with
available NMM and the use of both reversal agents. The
secondary goals were to examine the characteristics of the
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use of intraoperative NMM and different reversal agents
by the attending anesthesiologists, and to determine the
factors related to the patient and perioperative processes
on the development of RNMB in a real-life clinical setting.
2. Materials and Methods
This prospective observational study was initiated with
the approval of the Haydarpaşa Numune Training and
Research Hospital Clinical Research Ethics Committee’s
application date 24.02.2020 and decision number
HNEAH-KAEK 2020/KK/26. Written informed consent
was obtained from all patients.
2.1. Patients
Patients who were 18–80 years of age, in the ASA I-III risk
group, and scheduled to undergo orotracheal intubation
using NMBDs under general anesthesia were included in
this study.
Patients with neuromuscular disease, renal failure (GFR
<60), hepatic failure (INR >1.5), history of aminoglycoside
antibiotic use, pregnancy, planned postoperative followup in the intensive care unit, unplanned intensive care unit
admission, or any diversion from general anesthesia with
orotracheal intubation (e.g., anesthesia plan changed to the
use of supraglottic airway device or regional techniques)
were excluded from this study.
2.2. Protocol
Patient premedication and intraoperative anesthesia
applications were selected by the anesthesiologist who
monitored the patient. Intraoperative NMM and reversal
agent selection were also performed by the relevant
anesthesiologist. In line with the observational study
design, the doses of NMBDs and reversal agents were not
standardized.
The patient arrival time at the PACU was designated
as point zero (T0). In addition to the vital signs,
acceleromyography (TOF-Watch®-SX Monitor, Organon
Teknika, Dublin, Ireland) of the patient’s adductor pollicis
muscle was monitored by a trained PACU nurse who was
blinded to the study. The stimulation current was set at
50 mA. The average of two consecutive measurements
made at a frequency of 2 Hz, with four pulses of 0.2 ms
duration separated by 15 s, was recorded. If the difference
between measurements was more than 10%, additional
TOFR measurements (up to four values) were performed,
and the average of the two closest measurements was
taken. The patient’s arterial oxygen saturation (SpO2)
was measured using a pulse oximeter. Heart rate (HR),
systolic and diastolic blood pressure, and TOFR values
were recorded at 0, 10, 20, and 30 min (T0, T1, T2, and T3,
respectively). A TOFR < 0.9 was defined as RNMB. In the
presence of RNMB, additional reversal agents and their
doses, as considered necessary by the anesthesiologist,
were documented.

Following the completion of the protocol, patients’
demographic and perioperative data were recorded from
their pre- and intraoperative evaluations as follows:
• Height, weight, body mass index, age, sex,
comorbidities, ASA score, drugs used, doses and
timings of agents used in induction and maintenance
of anesthesia, type of NMBD used, induction dose and
total dose, number of additional doses, and timing.
• Whether NMM was performed on the patient,
the reversal agent administered at the end of the
operation, dose, and timing.
• Duration of anesthesia: The time between the start of
induction and the decision to transfer to the PACU.
• Reversal-PACU: Time between the first administration
of the reversal agent at the end of surgery and T0 in
the PACU.
• NMBD-PACU: Time between the last NMBD
administration and T0 in the PACU.
2.3. Statistical Analyses
Assuming that the incidence of RNMB would be at most
40%, the sample size, with alpha 0.05 and beta 0.1, was
calculated as 210 patients. With this sample size, the
predicted incidence could be estimated with a margin of
error of < 7% at the 95% confidence interval.
Categorical variables were compared using the chisquare test and are expressed as numbers and percentages.
Subgroups were compared using Bonferroni correction.
The distribution of continuous variables was evaluated
using the Shapiro–Wilk test. Normally distributed
variables were compared using the Student’s t-test and are
expressed as means and standard deviations. Continuous
variables without normal distribution were compared
using the Mann–Whitney U test and are expressed as
medians and 25th–75th percentiles. The binary logistic
regression test was used to evaluate the relationship
between risk factors and RNMB. To categorize continuous
variables in the regression analysis, receiver operating
characteristic (ROC) curve analysis was performed
to determine the optimal cutoff point using Youden’s
index (sensitivity + specificity – 1) and points at which
the specificity and sensitivity values were 90%. Four
groups were formed based on these three points. In all
statistical analyses, statistical significance was set at p <
0.05. Statistical analyses were performed using SPSS for
Windows, version 21.0 (SPSS Inc., Chicago, IL, USA) or
MedCalc, version 16.1 (MedCalc Software Ltd, Ostend,
Belgium), as appropriate.
3. Results
A total of 239 patients were included in the study, 216 of
whom completed the protocol (Figure). Rocuronium was
used as the neuromuscular blocking agent in all patients, and
all patients received a reversal agent at the end of surgery.
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According to the initial TOFR values measured in
the recovery room, RNMB was observed in 47 patients
(21.8%). Based on the development of RNMB, the patients
were allocated into two groups (RNMB and no-RNMB)
and compared. Data regarding the patients’ demographic
characteristics, comorbidities, surgical characteristics,
volatile agents used, and duration of anesthesia are given
in Table 1. Based on the first vital signs obtained in the
PACU, there was a significant difference in SpO2 and HR
values i n favor of the no-RNMB group (p = 0.007 and p <
0.001, respectively) (Table 2).
Seventy-eight patients (36%) were followed with
acceleromyography for NMM during the intraoperative
period. RNMB developed less frequently in these patients
compared with those who were not monitored (11.5% vs.
27.5%, p = 0.01). This difference, which was still observed
at T1 and T2, vanished at T3 (p values: 0.02, 0.05, and 0.55
for the aforementioned time points, respectively) (Table 3).
In 174 (80.5%) patients, neostigmine/atropine was
administered; in 42 patients (19.5%), sugammadex was
administered. In the sugammadex group, 35 of 42 patients
received a dose < 2 mg/kg. A lower incidence of RNMB was
observed in patients who received sugammadex compared
with those who received neostigmine (4.8% vs. 25.9%,
p = 0.006). The rocuronium doses administered during
induction and throughout the surgery, the total number of
additional NMBD doses, NMBD-PACU duration, reversal
agents administered and their doses, and reversal-PACU
duration in the RNMB and no-RNMB groups are shown
in Table 4.

Patients screened
(n = 239)

Patients were allocated into four groups according to
whether they were followed with NMM and the reversal
agent used:
• NMM was applied, neostigmine was used (N+); n = 49.
• No NMM, neostigmine was used (N−); n = 125.
• NMM was applied, sugammadex was used (S+); n = 29.
• No NMM, sugammadex was used (S−); n = 13.
The incidences of RNMB in these groups were 18%,
28%, 0%, and 15%, respectively (p = 0.006). In the
subgroup analysis, only the difference between the S+ and
N− groups was statistically significant (p = 0.001).
Three patients in the N− group had TOFR values
of 0.65, 0.63, and 0.67, and an additional 1-mg dose of
neostigmine was administered to these patients. When the
T3 TOFR values were examined, the TOFR value was >
0.9 in one patient, and RNMB persisted in the other two
(TOFR: 0.85, 0.82). Except for these three patients, none
received any additional doses, as the attending clinicians
preferred to follow the patients in their existing state
instead of intervening with additional doses.
Eight patients had TOFR values of 0.70–0.79; all were
in the N− group. The attending anesthesiologists also
preferred to follow these patients in their existing state
without intervention. They were all under RNMB at T1,
while two had recovered at T2, and all had TOFRs > 0.9
at T3.
The TOFR values of
 two patients in the S− group with
RNMB were 0.86 and 0.82 at T0. The TOFR values of these
two patients were > 0.9 at T1. The doses of sugammadex
administered to these patients were 1.1 mg/kg and 3.2

Excluded patients (n = 20)
• ASA > 3 (2)
• Pregnancy (2)
• GFR < 60 ml / min (3)
• Regional anesthesia applied (4)
• SGA device applied (4)
• Unplanned ICU admission (5)

Patients entered study
(n = 219)
Lost to follow-up (n = 3)
• TOFR measurement failed (3)
Patients completed study
(n= 216)
Figure. Study flow-chart.
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Table 1. Characteristics of patients.
All (216)

RNMB (47)

No-RNMB (169)

p-value

Sex (M/F)

110/106

24/23

86/83

0.98

Age

50.9 ± 13.2

52 ± 15

51 ± 13

0.52

BMI (kg/m2)

27.9 (24.8–31.2)

28.6 (24.6–32.4)

27.7 (24.8–31)

0.67

ASA Score (1 & 2 / 3)

178/38

37/10

141/28

0.51

Nonsmoker

153 (71%)

35 (74%)

118 (70%)

0.66

Hypertension

53 (%25)

12 (%26)

41 (%24)

0.85

Diabetes mellitus

48 (%22)

12 (%26)

36 (%21)

0.55

Coronary artery disease

27 (%13)

4 (%9)

23 (%14)

0.46

Pulmonary diseases

17 (%8)

1 (%2)

16 (%10)

0.13

Malignancy

27 (%13)

9 (%19)

18 (%11)

0.14

Thyroid dysfunctions

22 (%10)

2 (%4)

20 (%12)

0.18

Duration of anesthesia (min)

163 ± 65

176 ± 68

159 ± 63

0.10

Comorbidities

Volatile agent

0.86

Sevoflurane

168 (%78)

37 (%79)

131 (%76)

Desflurane

48 (%22)

10 (%21)

38 (%24)

General surgery

113 (%52)

26 (%55)

87 (%51)

Gynecology

38 (%18)

6 (%13)

32 (%19)

Urology

28 (%13)

5 (%11)

23 (%14)

Orthopedic

37 (%17)

10 (%21)

27 (%16)

Surgery group

0.62

Qualitative data are expressed as number and percentage of case, and compared with chi-squared test. Normally distributed
data are expressed as mean ± SD, and compared with Student’s t-test. Nonnormally distributed data are expressed as median
(25th to 75th percentile), and compared with the Mann–Whitney U test. RNMB: residual neuromuscular block, ASA score:
American Society of Anesthesiologists score, BMI: body mass index

Table 2. Vital parameters of patients recorded following the arrival at PACU.
RNMB (47)

No-RNMB (169)

p-value

SpO2 (%)

96.74 ± 1.52

97.36 ± 0.96

0.007

Systolic AP (mmHg)

126.81 ± 23.25

128.62 ± 14.71

0.113

Diastolic AP (mmHg)

68.43 ± 11.73

67.22 ± 8.65

0.798

Mean AP (mmHg)

86.35 ± 13.07

86.46 ± 9.90

0.371

Heart rate (1/min)

79.96 ± 6.08

74.98 ± 8.33

<0.001

Data are expressed as mean ± SD, and compared with Student’s t-test. PACU: postoperative anesthesia care unit, RNMB:
residual neuromuscular block, SpO2: oxygen saturation of arterial blood measured by pulse oximeter, AP: arterial
pressure
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Table 3. Residual neuromuscular block incidence and train of four ratios according to neuromuscular monitoring application.
NMM

No-NMM

p-value

T0-RNMB incidence

9 (11.5%)

38 (27.5%)

0.01

T1-RNMB incidence

2 (2.6%)

25 (18.1%)

0.002

T2-RNMB incidence

0

12 (8.7%)

0.005

T3-RNMB incidence

0

3 (2.2%)

0.56

T0-TOF ratio

0.93 ± 0.04

0.89 ± 0.06

<0.001

T1-TOF ratio

0.96 ± 0.04

0.93 ± 0.05

<0.001

T2-TOF ratio

0.99 ± 0.04

0.96 ± 0.04

<0.001

T3-TOF ratio

1.01 ± 0.04

1.00 ± 0.05

0.004

Qualitative data are expressed as number and percentage of case, and compared with chi-squared test. Normally distributed
data are expressed as mean ± SD, and compared with Student’s t-test. NMM: neuromuscular monitoring, RNMB: residual
neuromuscular block, TOF: train of four

Table 4. Perioperative management of neuromuscular junction.
All (216)

RNMB (47)

No-RNMB (169)

p-value

Induction dose (mg/kg)

0.65 ± 0.09

0.65 ± 0.08

0.65 ± 0.10

0.65

Total dose (mg/kg)

0.77 ± 0.21

0.83 ± 0.20

0.75 ± 0.20

0.03

Total dose (mg/kg/60 min)

0.30 (0.24–0.35)

0.29 (0.24–0.36)

0.30 (0.25–0.35)

0.71

0

103 (%48)

12 (26%)

91 (54%)

1

63 (%29)

18 (38%)

45 (26%)

2

28 (%13)

10 (21%)

18 (11%)

3

15 (%7)

5 (11%)

10 (6%)

4

7 (%3)

2 (4%)

5 (3%)

Doses of NMBD

Number of additional doses

0.01

Drug used for reversal

0.006

Neostigmine

174 (81%)

45 (96%)

129 (76%)

Sugammadex

42 (19%)

2 (4%)

40 (24%)

Neostigmine (mcg/kg)

21.2 ± 3.0

20.3 ± 2.5

21.5 ± 3.2

0.02

Sugammadex (mg/kg)

1.5 ± 0.7

1.1–3.2

2.2 ± 1.5

N/A

Doses of reversal agents

Neuromuscular monitoring

0.01

Yes

78 (%36)

9 (19%)

69 (41%)

No

138 (%64)

38 (81%)

100 (59%)

Reverse-PACU duration (min)

12.1 ± 3.6

13.6 ± 3.6

11.7 ± 3.5

0.001

NMBD-PACU duration (min)

104 ± 42

84 ± 35

110 ± 42

<0.001

Qualitative data are expressed as number and percentage of case, and compared with chi-squared test. Normally distributed data are
expressed as mean ± SD, and compared with Student’s t-test. Nonnormally distributed data are expressed as median (25th to 75th
percentile), and compared with the Mann–Whitney U test. Sugammadex dose in RNMB group is expressed as min–max. NMBD:
neuromuscular blocking drug, PACU: Postoperative anesthesia care unit. Reverse-PACU duration: Time between the first application
of the reversal agent at the end of the surgery and the recording of firs measurements in PACU. NMBD-PACU duration: Time between
the application of the last dose of NMBD application and the recording of firs measurements in PACU.
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mg/kg, respectively. The duration of anesthesia and total
rocuronium dose of the latter patient were 292 min and
1.4 mg/kg, respectively. None of the patients in the S+
group experienced RNMB despite the low doses used for
sugammadex.
The following variables were included in the binary
logistic regression analysis to evaluate the relationship
between these variables and the occurrence of RNMB:
the number of additional NMBD doses (reference value:
zero additional doses), whether intraoperative NMM
was performed (reference value: NMM was performed),
reversal agent administered (reference value: sugammadex
used), and NMBD-PACU (reference value: 0–50 min). The
NMBD-PACU was categorized as 0–50 min, 51–87 min,
88–144 min, and 145+ min according to the points on the
ROC curve defined in the Materials and Methods section.
The probability ratios, confidence intervals, and p values
of the related variables are presented in Table 5. A NMBDPACU value < 88 min was significantly related to increased
risk for RNMB (OR ≥ 7.6; p ≤ 0.001).
4. Discussion
In this study, RNMB was detected in 21.8% of the
patients. In studies using the TOFR < 0.9 threshold, the

incidence of RNMB varies greatly from 13% to 88% [16]. This discrepancy between the reported values may

be
due to substantial differences in study methodology and
protocols, such as the application of intraoperative NMM,
type of NMM equipment used, waiting for spontaneous
recovery vs. intervention with a reversal agent, and type
and dose of the reversal agent used.
NMM was applied to 78 (36%) of the patients, and
the incidence of RNMB was higher in non-monitored
patients (27.5% vs. 11.5%, p = 0.01; OR: 2.65, p = 0.03).
Similarly, in the study conducted by Murphy et al., the
incidence of RNMB was lower in patients who underwent
intraoperative NMM (14.5% vs. 50.0%, p < 0.0001) [12].
Baillard et al. showed that RNMB incidence could decrease
from 62% to 3% after training for the use of NMM and
proper use of reversal agents [13].
The 21.8% incidence of RNMB despite NMM
application in our study can be explained by the dose,
timing, and duration to peak effect of the reversal agents
administered. The neostigmine doses administered in our
study (21.2 ± 3.0 mcg/kg) were below the recommended 40
mcg/kg [9]. The tendency of anesthesiologists to administer
low doses of neostigmine may be because neostigmine
doses of ≥ 2.5 mg can increase the incidence of nausea,

Table 5. Multivariable logistic regression analysis for the association between residual neuromuscular blockade and potentially
related factors.
Odds ratio

95% CI

p-value

Sugammadex

1

reference

Neostigmine

443.5

10.7-18355.2

Yes

1

reference

No

3.9

1.4-10.8

145 +

1

reference

88–144

0.5

0.1-1.6

0.24

51–87

7.6

2.2-26.6

0.001

0–50

104.2

3.3-3300.2

0.008

0

1

reference

1

1.4

0.5–4.2

0.5

2

4.4

1.2–15.5

0.02

3

9.4

1.3–70.9

0.03

4

112.3

3.8–3286.6

0.006

Drug used for reversal
0.001

Use of NMM
0.01

NMBD-PACU duration (min)

Additional NMBD doses

CI: confidence interval, NMM: neuromuscular monitoring, NMBD: neuromuscular blocking drug, NMBD-PACU duration:
Time between the application of the last dose of NMBD application and the recording of firs measurements in PACU.
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vomiting, and other anticholinergic effects [14, 15]. In
addition, Caldwell et al. reported that when neostigmine
is administered to a patient who has nearly or completely
recovered from a neuromuscular block, it may decrease
TOFR and cause muscle weakness as a result of prolonged
paradoxical neuromuscular block [16]. In a study of the
duration to peak effect of neostigmine, Della Rocca et al.
revealed that the times to reach TOFR ≥ 0.9 for patients
with a superficial block (TOF count: 2) and deep block
are 7.8 min (0.5–37.8 min) and 20.6 min (1.8–41.3 min),
respectively [11]. Based on these data, we can conclude
that anesthesiologists prefer to wait for spontaneous
recovery instead of administering an additional dose in
cases of asymptomatic RNMB. Thus, despite the similar
neostigmine doses in patients with and without RNMB,
the longer reversal-PACU time (13.6 ± 3.6 min vs. 11.7 ±
3.5 min, p = 0.001) in the RNMB group seems to be due to
the longer recovery time of these patients. We can assume
that these patients were inadequately reversed, spent
more time in the operating room due to struggles during
recovery, and were still under RNMB when arriving at the
PACU.
In our study, sugammadex was used in 42 (19.4%)
patients. The attending anesthesiologists preferred a
sugammadex dose less than the recommended 2 mg/
kg in 35 (83%) of them. Schaller et al. revealed that a
sugammadex dose of 0.22 mg/kg is sufficient to reverse
a shallow block, defined as TOFR 0.5 [17]. In addition,
researchers have found that when the TOF count is
2–4 (moderate block), a sugammadex dose of 1 mg/kg
can be safely used for reversal [18]. Considering these
findings, attending anesthesiologists might have preferred
lower doses of sugammadex based on NMM results or
their clinical experience. Additionally, the high cost of
sugammadex, when compared to that of neostigmine
might have been a reason for underdosing.
We observed RNMB in 2 (4.8%) patients who received
sugammadex. One was underdosed (1.1 mg/kg), while
the other received a dose expected to be sufficient (3.2
mg/kg). Neither of these patients underwent NMM.
RNMB was not observed in any patient who underwent
NMM and received sugammadex. Kotake et al. found
a 9.4% incidence of RNMB in patients who did not
undergo NMM and were administered sugammadex [19].
Understandably, although the use of sugammadex reduces
RNMB, it cannot guarantee safe extubation in the absence
of NMM [19, 20].
Factors that increase the risk of RNMB include
the number of doses and the timing of the last dose of
NMBD [21]. In our study, the probability of developing
RNMB gradually increased as the NMBD-PACU duration
shortened and the number of additional NMBD doses
increased, starting from the second additional dose
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(Table 3). Our results indicate that increased risk for
RNMB may last up to 88 min after the last administered
rocuronium dose. Similarly, Naguib et al. showed that high
and additional doses of NMBD administration and short
NMBD-PACU duration increased the cumulative effect
and risk of RNMB [22].
We believe that this study contributes to the literature
in several ways. To the best of our knowledge, this is
the first study evaluating attending anesthesiologists’
preferences regarding the dosing of both neostigmine
and sugammadex and the use of NMM after the last
guideline published in 2020 [9]. It is interesting to note
that specialists continue to prefer lower neostigmine
doses despite the recommendations. Further studies are
needed to clarify the safety of neostigmine doses > 40
mcg/kg. Additionally, our study revealed that when NMM
is applied, RNMB is not expected even when the dose
of sugammadex is lowered (<2 mg/kg). Lastly, our study
revealed a significantly increased risk for RNMB for 88
min after the last administered dose of rocuronium. This
is the first study to reveal such a duration for rocuronium
as an independent risk factor for RNMB.
This study has certain limitations. Firstly, patients
with an ASA score > 3 and those who required intensive
care unit admission in the postoperative period, were not
included in the study. The response of these patients to
the agents used may lead to different results. Secondly, the
intraoperative period, interventions for RNMB diagnosis,
agents used, and doses were not standardized. Different
results may be obtained in a standardized study. However,
our approach reflected real-life situations; therefore,
the findings are valuable. Thirdly, postoperative TOFR
measurements were performed using a nonprecalibrated
TOF-Watch®-SX monitor. As the monitor was set up when
the patient arrived in the recovery room, it could not be
calibrated by taking supramaximal flow values 
before
NMBD administration. However, this monitor’s basic
configuration provides adequate sensitivity for most adult
patients; this device has been used without calibration
in many studies in which NMM was performed in the
recovery room [4, 8, 20)].
5. Conclusions
In our study, the RNMB incidence was found to be 21.8%
in a tertiary care hospital with available NMM and the
use of the reversal agents, neostigmine and sugammadex.
Despite strong recommendations, the use of NMM is still
insufficient and reversal agents are still underdosed. Lack
of intraoperative quantitative NMM, use of neostigmine
instead of sugammadex, multiple additional doses, and
administration less than 88 min after the last dose of
NMBD were identified as risk factors for RNMB. Further
efforts should aim towards increasing awareness of RNMB
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and promoting the routine and proper use of NMM and
reversal drugs.
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